Publication

Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma

Halwani, A. S.
; 
Panizo, C.
; 
Isufi, I.
; 
Herrera, A. F.
; 
Okada, C. Y.
; 
Cull, E. H.
; 
Kis, B.
; 
Chaves, J. M.
; 
Bartlett, N. L.
; 
Ai, W.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Halwani, A. S.
Panizo, C.
Isufi, I.
Herrera, A. F.
Okada, C. Y.
Cull, E. H.
Kis, B.
Chaves, J. M.
Bartlett, N. L.
Ai, W.
de la Cruz-Merino, L.
Bryan, L. J.
Houot, R.
Linton, Kim M
Briones, J.
Chau, I.
von Keudell, G. R.
Lu, H.
Yakovich, A.
Chen, M.
Meulen, J. H. T.
Yurasov, S.
Hsu, F. J.
Flowers, C. R.
Affiliation
Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA
Description
Date
2021
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, et al. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma Leukemia & Lymphoma. Informa UK Limited; 2021. p. 1–13.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/624957
Embedded videos